FDA Approvals

The US Food and Drug Administration (FDA) has approved a therapy for adults with relapsed or refractory acute myeloid leukemia (AML) with a specific genetic mutation.

The US Food and Drug Administration (FDA) had granted expanded approval of a melanoma drug to include pediatric patients.

The US Food and Drug Administration (FDA) has approved a treatment demonstrated to reduce the risk of disease recurrence in patients with early-stage, human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

The US Food and Drug Administration (FDA) has granted full approval to a treatment for B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children.

The US Food and Drug Administration (FDA) has approved the first and only antibody for the treatment of a type of colorectal cancer.

The US Food and Drug Administration (FDA) has approved an immunotherapy in combination with two other therapies for the treatment of multiple myeloma.

The US Food and Drug Administration (FDA) granted accelerated approval to a treatment for patients whose tumors have a specific biomarker, rather than a shared location in the body.

The US Food and Drug Administration (FDA) has granted accelerated approval to first-line pembrolizumab for urothelial carcinoma.

The US Food and Drug Administration (FDA) has approved a combination pack with 2 prescription products for the treatment of advanced breast cancer.